Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial
Ethan Basch(UNC Lineberger Comprehensive Cancer Center), Charles S. Cleeland(The University of Texas MD Anderson Cancer Center), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Charles J. Ryan(University of Minnesota), Michael L. Meyers(Eastern Cooperative Oncology Group), Paul N. Mainwaring(Australasia Paediatric Endocrine Group), Susan Li(Janssen (United States)), Thian Kheoh(Janssen (United States)), Neal D. Shore(Carolina Urologic Research Center), Karen A. Autio(Memorial Sloan Kettering Cancer Center), Yanni Hao(Janssen (United States)), Peter Mulders(Radboud University Nijmegen), Arturo Molina(Janssen (United States)), Matthew R. Smith(Harvard University), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), Thomas W. Griffin(Janssen (Belgium)), Karim Fizazi(Université de Lille)
Cited by 153
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k